Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  EuroIntervention

• Publication date

  2016-11-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.4244/EIJY15M11_07PMID 26606735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term use of ticagrelor in patients with prior myocardial infarction.

  2015cited by this paper
• 2014 ESC/EACTS guidelines on myocardial revascularization.

  2015cited by this paper
• Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.

  2015cited by this paper
• Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials

  2015cited by this paper
• Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

  2014cited by this paper
• Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.

  2014cited by this paper
• Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials.

  2013cited by this paper
• Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study

  2012cited by this paper
• Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial

  2012cited by this paper
• A prospective natural-history study of coronary atherosclerosis.

  2011cited by this paper
• Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium

  2011cited by this paper
• Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor

  2011cited by this paper
• Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.

  2011cited by this paper
• Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

  2011cited by this paper
• In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

  2011cited by this paper
• Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.

  2011cited by this paper
• Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

  2010cited by this paper
• Duration of dual antiplatelet therapy after implantation of drug-eluting stents.

  2010cited by this paper
• Assessment of the SYNTAX score in the Syntax study.

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.

  2008cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

  2006cited by this paper
• The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.

  2005cited by this paper
• A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.

  2004cited by this paper
• A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry

  2004cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• Significance of the Diagnostic Q Wave of Myocardial Infarction

  1971cited by this paper

• De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome

  2025cites this paper
• Tratamiento de la angina estable

  2025cites this paper
• Mitochondria, Sex, and Cardiovascular Disease: A Complex Interplay

  2025cites this paper
• Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy?

  2025cites this paper
• 2024 ESC Guidelines for the management of chronic coronary syndromes.

  2024cites this paper
• Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

  2022cites this paper
• Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial

  2022cites this paper
• Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY.

  2021cites this paper
• 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations

  2021cites this paper
• Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial

  2021cites this paper
• ‘Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI’: a post hoc analysis of the randomized GLOBAL LEADERS trial

  2021cites this paper
• External validation of the GRACE risk score 2.0 in the contemporary all‐comers GLOBAL LEADERS trial

  2021cites this paper
• Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade—why it could be a novel paradigm?

  2021cites this paper
• Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond

  2021cites this paper
• Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial.

  2020cites this paper
• The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

  2020cites this paper
• Impact of Ticagrelor Monotherapy on Two-Year Clinical Outcomes in Patients with Long Stenting: A Post Hoc Analysis of the Global Leaders Trial.

  2020cites this paper
• Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

  2020cites this paper
• Usefulness of updated logistic clinical SYNTAX score based on MI‐SYNTAX score in patients with ST‐elevation myocardial infarction

  2020cites this paper
• Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).

  2020cites this paper
• Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial

  2020cites this paper
• Regional variation in patients and outcomes in the GLOBAL LEADERS trial.

  2020cites this paper
• Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events

  2020cites this paper
• Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial.

  2020cites this paper
• Can we offer tailor-made pharmacological treatment of patients with acute coronary syndrome?

  2020cites this paper
• Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events

  2020cites this paper
• Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin

  2020cites this paper
• The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial.

  2020cites this paper
• Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis

  2020cites this paper
• with clinical after following in :

  2020cites this paper
• Twilight, the Dawn of a New Era of Aspirin-Free PCI?

  2020cites this paper
• 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)

  2020influential citation
• Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial

  2020cites this paper
• Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti‐platelet therapy

  2020cites this paper
• Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.

  2019cites this paper
• Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing?

  2019cites this paper
• Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy☆

  2019cites this paper
• Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience

  2019cites this paper
• Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

  2019cites this paper
• Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial.

  2019cites this paper
• Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.

  2019cites this paper
• Antiplatelet Drugs in the Management of Coronary Artery Disease

  2019cites this paper
• Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention

  2019cites this paper
• Tratamiento antitromb�tico sin �cido acetilsalic�lico tras implante de stent: �mito o realidad?

  2019cites this paper
• Clinical relevance of ticagrelor monotherapy following 1‐month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial

  2019cites this paper
• Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.

  2019cites this paper
• Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial).

  2019cites this paper
• Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.

  2019cites this paper
• Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.

  2019cites this paper
• Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS.

  2019cites this paper
• Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

  2019cites this paper
• Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial.

  2019cites this paper
• Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial.

  2019influential citation
• 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

  2019cites this paper
• 21 – Antiplatelet and Anticoagulant Drugs

  2018cites this paper
• Platelet responses to pharmacological and physiological interventions in middle‐aged men with different habitual physical activity levels

  2018cites this paper
• Stent thrombosis in patients with drug‑‑eluting stents and bioresorbable vascular scaffolds: the feared complication.

  2018cites this paper
• Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document.

  2018cites this paper
• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.]

  2018cites this paper
• Quo vadis, aspirin?

  2018cites this paper
• Interventional cardiology: review of the year 2017.

  2018cites this paper
• Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician.

  2018cites this paper
• Early vascular responses to everolimus-eluting cobalt–chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study)

  2018cites this paper
• The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts

  2018cites this paper
• Current and future antiplatelet therapies: emphasis on preserving haemostasis

  2018cites this paper
• Application of the MADS classification system in a “mega mammoth” stent trial: Feasibility and preliminary clinical implications

  2018cites this paper
• Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.

  2018cites this paper
• An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction

  2018cites this paper
• Impact of high on‐aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug‐eluting stents

  2018cites this paper
• Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS

  2018cites this paper
• OP-EUPA180177 1..27

  2018cites this paper
• Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.

  2018cites this paper
• Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

  2018cites this paper
• Clash of Oral P2Y12 Receptor Inhibitors in Acute Coronary Syndromes.

  2018cites this paper
• Individualized antithrombotic therapy in high-risk cardiovascular patients.

  2018cites this paper
• Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice

  2018cites this paper
• 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European

  2018cites this paper
• 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

  2018cites this paper
• Aspirin withdrawal in patients treated with ticagrelor presenting with non‐ST elevation myocardial infarction

  2018cites this paper
• The development of antiplatelet therapy after percutaneous coronary intervention

  2017cites this paper
• Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study.

  2017cites this paper
• Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis.

  2017cites this paper
• Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine

  2017cites this paper
• Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.

  2017cites this paper
• Associations between Complex PCI and Prasugrel or Clopidogrel use in Patients with Acute Coronary Syndromes undergoing PCI: From the PROMETHEUS Study

  2017cites this paper
• Influence of P2Y12 Inhibitors and Statins on Cardiovascular Risk Factors in Patients after PCI

  2017influential citation
• Update on antithrombotic therapy after percutaneous coronary revascularisation.

  2017cites this paper
• Acute Coronary Stent Thrombosis in Modern Era: Etiology, Treatment, and Prognosis

  2017cites this paper
• One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper

  2017cites this paper
• GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.

  2017cites this paper
• Single or dual antiplatelet therapy after PCI

  2017cites this paper
• Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.

  2017cites this paper
• State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives.

  2017cites this paper
• Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial

  2017cites this paper
• Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.

  2017cites this paper
• Resultados clínicos del uso de los nuevos antiagregantes en la vida real

  2017cites this paper
• Indicación del tratamiento con doble antiagregación más allá del año. A quién y por qué

  2017cites this paper
• Antithrombotic therapy for acute coronary syndrome: Past, present and future

  2017influential citation
• Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease

  2016cites this paper
• Freedom from long DAPT signals the demise of the bare-metal stent

  2016cites this paper